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We offer a critique of what constitutes a suitable dosage limit, in both clinical 
and preclinical studies, for interstitially administered magnetic nanoparticles in 
order to enable therapeutic hyperthermia under the action of an externally applied 
alternating magnetic field. We approach this first from the perspective of the 
currently approved clinical dosages of magnetic nanoparticles in the fields of 
MRI contrast enhancement, sentinel node detection, iron replacement therapy and 
magnetic thermoablation. We compare this to a simple analytical model of the 
achievable hyperthermia temperature rise in both humans and animals based on 
the interstitially administered dose, the heating and dispersion characteristics of 
the injected fluid, and the strength and frequency of the applied magnetic field. 
We show that under appropriately chosen conditions a therapeutic temperature 
rise is achievable in clinically relevant situations. We also show that in such cases 
it may paradoxically be harder to achieve the same therapeutic temperature rise in 
a preclinical model. We comment on the implications for the evidence-based 
translation of hyperthermia based interventions from the laboratory to the clinic.   
Keywords: magnetic hyperthermia; magnetic nanoparticles; SPIONs. 
1. Introduction 
Although it is now sixty years since the concept of magnetic hyperthermia as a 
therapeutic modality was first proposed [1], and a decade or more since the first clinical 
results were reported [2, 3], it is clear that it is of significant current interest. In the year 
2015 alone, more than 750 scientific and clinical papers were published on magnetic 
hyperthermia [4], which surely reflects the substantial world-wide R&D effort that has 
been devoted to the field in recent years. This effort has been accompanied by 
significant funding at both national and international levels – the latter exemplified by 
the ca. EUR 40 million that the European Commission has allocated in the area in the 
last five years [5].  
One likely reason for the large scale of this funding is that the research is 
increasingly moving beyond laboratory-scale experiments, towards preclinical studies 
with a variety of animal models, and in some cases even further, towards full-scale 
clinical studies, with all of the complexity and cost that this entails [6]. As such it is 
more important than ever for researchers to address the translational research 
imperatives of constructing appropriately scalable animal model experiments that 
generate data of a quality and relevance suitable for an ethics committee or a clinical 
R&D approvals committee. It is only when clear and cogent arguments can be made to 
link promising preclinical results to an expected advantageous outcome in man that 
clinical studies may be suitably designed, approvals sought and granted, and the study 
itself successfully undertaken and completed. 
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In this context it is perhaps surprising that – to our knowledge at least – there is 
very little available in the literature regarding the practicalities of designing for the 
transition from preclinical to clinical studies of magnetic hyperthermia. There are a 
great many published works that report on preclinical models in isolation, but very few 
that take the next step to explain how to get from the animal model to man. Even in 
cases where the step has perforce been taken – such as in the work of Andreas Jordan 
and colleagues at MagForce AG in Berlin [2, 3] – the process has not been spelled out 
in a way that makes it accessible or comprehensible to others. It may be that the reason 
for this is that it is impossible to provide a simplistic ‘one size fits all’ solution for an 
extremely varied field in which there are numerous different clinical indications 
requiring very different materials, administration routes, formulations and medical 
device architectures – and that it is not useful to try to draw any generally applicable 
conclusions on the matter. However, in our opinion this is a subject that should be 
considered and discussed, even if at the same time we acknowledge that every study 
will be unique unto itself, and every study protocol – both preclinical and clinical – will 
still need to be evaluated on its own merit. 
With this in mind, we present here a commentary on the question of what is an 
acceptable dosage for the interstitial injection of a magnetic fluid in both a preclinical 
model and in a clinical study of magnetic hyperthermia. We focus on interstitial 
administration rather than systemic intravenous injection on the basis that the former is 
both a much less complex route to clinical translation, and a more effective one. Where 
it is helpful to do so, we include descriptions of current practice for intravenous 
administration, to compare and contrast with the case for interstitial administration. We 
provide evidence to support our position based on both current regulatory and clinical 
practice, and on theoretical biophysical modelling of the heat flows associated with 
therapeutic magnetic hyperthermia and/or thermoablation. 
2. Interstitial versus intravenous administration    
We begin by commenting further on our rationale for focusing on interstitial rather than 
intravenous administration, which brings up several central issues of significance, viz. in 
relation to formulation challenges, therapeutic efficacy, intended primary mode of 
action, adverse effect levels and preclinical-to-clinical scaling, and species-dependent 
local guidelines on maximum injection volumes.  
2.1 Interstitial administration may allow less complex formulation 
Iron oxide particles presenting in the bloodstream inherently come into direct contact 
with the body’s reticuloendothelial system (especially those elements in the blood, 
spleen, and liver), so that blood clearance times can be very short [7]. For this reason, 
with intravenous administration, an additional step of surface functionalisation of the 
nanoparticles is usually pursued, in an effort to produce ‘stealth’ particles. This may 
well be effective [8], but it undoubtedly adds to the complexity of the material. There 
are also issues related to the presence of any inorganic nanomaterial in the blood, such 
as the inducement of a protein corona effect, or of complement activation (a protein-
mediated proxy stimulation of an immune response), that should preferably be avoided 
or at least controlled [9]. These all add to the challenges of gathering sufficient safety-
related evidence to secure the ethical and regulatory approvals required before clinical 
studies may be conducted.  
The corresponding situation for interstitial injection is not entirely different – 
after all, magnetic fluids injected into tissue, such as a tumour stroma, or the adjacent 
connective tissue, will still encounter active agents of the reticuloendothelial system, 
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especially those macrophages that pass through the extracellular matrix. However, the 
direct injection route allows for greater flexibility in the choice of the surface chemistry 
of the particles, including non-functionalised particles – such as the aminosilane-coated 
iron oxide nanoparticles used by MagForce [10] – that would be quickly taken up in the 
liver or spleen if they were delivered intravenously. Also, it should not be overlooked 
that it may well be a desirable aspect of the use of magnetic nanoparticles that the body 
does, over time (weeks or months), metabolise and clear the material away from the 
injection site.  
2.2 Interstitial administration may be more effective  
It has long been recognised that individual magnetic nanoparticles cannot deliver 
sufficient heat to be effective [11]. The problem is a fundamental one: to be good 
magnetic heaters, the particles need to be small – typically 10-30 nm in diameter – so 
that they contain only a single magnetic domain at body temperature [12]. (Multi-
domain particles contain magnetic domain walls that can be relatively easily moved in a 
time-varying magnetic field, limiting the energy dissipation that is needed to generate 
heat.) However, this small size means that their surface area to volume ratio is large, so 
that heat dissipation is rapid and thermal equilibration with the environment almost 
instantaneous [13]. The only way to overcome this is to have an ensemble of 
nanoparticles at the target site, acting in unison, so that the summed action of the 
distributed heat sources may together raise the temperature of the local environment.  
Even in such cases, substantial local concentrations of nanoparticles are needed. 
Hergt and Dutz estimated that with the then state-of-the-art materials and appliances, 
viz. those with a heat transfer rate of 100 W/gFeOx (where the subscript ‘FeOx’ denotes 
the heat-generating magnetite and/or maghemite iron oxide nanoparticles), a local 
concentration of ca. 10 mgFeOx/ml would be needed to heat an 11 mm diameter tumour 
by ΔT = 15 K, while ca. 40 mgFeOx/ml would be needed to heat a 3 mm diameter 
tumouroid (at the diagnostic size limit for metastatic cancer) by ΔT = 5 K [11]. Such 
high concentrations are conceivable following interstitial injection, but – to date at least 
– they are very challenging after intravenous injection, where an extremely effective 
(and not yet realised) local trapping and retention mechanism would need to be 
employed. This applies both to the lower threshold of achieving the ΔT » 6 K required 
for clinical hyperthermia (an operating temperature in vivo of 43 °C), as typically 
employed as an adjuvant to chemotherapy or radiotherapy [14, 15], and even more so 
for the higher threshold of ΔT ≥ 23 K required for the more demanding therapeutic 
treatment of thermoablation, which requires an operating temperature in vivo of 60 °C 
or more [16].  
2.2.1 Factors affecting the dispersion of magnetic nanoparticles in tissue   
A corollary of the requirement for there to be a substantial local concentration of 
magnetic nanoparticles at the treatment site is that the dispersion of the particles into the 
tissue, in and around the injection site, is a determining feature of the procedure. This is 
a complex field of research, where the physical factors of the procedure (such as the 
tissue density and porosity, the catheter size, design and placement, and the infusion 
rate and volume), and the physicochemical properties of the magnetic fluid (such as the 
particle size, charge and surface coating, and the osmolality, viscosity and concentration 
of the fluid as a whole), all contribute and are all inter-related. Operational issues such 
as the volume of the injectate or infusate relative to the tolerable tissue-loading limit 
(which varies between tissue types and from site to site in the body), the potential for 
tissue damage if the infusion rate is too high, and backflow (a.k.a. reflux) along the 
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needle path leading to leakage of the infusate away from the intended site, are also 
factors to be considered and controlled.  
The question of the homogeneity of the dispersion is a challenging one, as 
ideally the distribution should be as uniform as possible, to simplify the process of 
modelling and predicting the dose-response characteristics of the hyperthermia 
treatment. However, this is not easy to achieve, as typically the target tissue (e.g. a 
tumour) is itself heterogeneous, and in any case, the interstitial administration of any 
fluid will naturally result in a higher concentration of material near the tip of the needle 
than at a distance further removed from the tip. That said, there are strategies (discussed 
in more detail in Section 2.2.3) that can be adopted to abrogate these effects, including 
the use of slow infusion rates [17-21] and reflux-resistant catheters [20, 22], and 
performing multiple-site small-volume injections rather than a single large-volume 
injection [2, 3, 10, 23]. Theoretical models of the diffusion mehanistics can also be 
called upon to help understand the process and design best-practice administration 
protocols [23, 24].   
2.2.2 Defining and measuring the interstitial dispersion factor, Vd/Vi   
A positive aspect of the situation is that in practical terms the post-administration 
outcome is an experimentally measurable quantity: viz. the dispersion factor Vd/Vi , 
where Vd is the tissue volume throughout which the injected material is dispersed, and 
Vi is the volume of fluid injected. As such, it is at least in principle possible to 
determine the optimum delivery conditions via post-hoc assessment and serial 
refinement. Indeed, Vd/Vi  is measurable, depending on the nature of the fluid, in a 
number of ways, including in vivo methods such as magnetic resonance imaging (MRI), 
magnetic particle imaging (MPI), or X-ray computed tomography (CT) imaging, or ex 
vivo methods such as histochemistry or histopathology.  
For clinical translation, the MRI and CT methods are attractive in that they are 
already routinely available world-wide, whereas while MPI is a promising emerging 
modality [25], it has a long way to go before it might become established in clinical 
settings. Regarding MRI versus CT, at first sight it might seem that MRI would be the 
natural modality to use, given that it is very sensitive to iron oxide nanoparticles, some 
of which are or have been used as intravenous T1 and T2* contrast agents [26]. 
However, this sensitivity leads to extensive artefacts in the MRI images obtained of 
locally concentrated magnetic particles [27], which makes quantification difficult. For 
this reason, CT imaging is the preferred modality. This applies both to clinical CT 
studies, such as those undertaken by the MagForce team as part of their patient-specific 
treatment planning [10, 28-30], and also to preclinical micro-focused CT studies [18, 
31-33].  
The key advantage for both CT and micro-CT is that the Vd/Vi  dispersion factor 
is quantifiable in terms of the observed iron concentration in the tissue (measured in 
mgFe/mltissue), since the presence of the iron significantly affects the local value of the 
X-ray attenuation coefficient µ. This in turn is related to the greyscale contrast in any 
given X-ray scanner via the industry-standard Hounsfield Unit (HU) scale, which is a 
linear transformation in which the radiodensity of distilled water is defined as zero HU, 
and the radiodensity of air is defined as -1000 HU. In a voxel with average linear 
attenuation coefficient µ: 
 HU = 1000 ´ (µ – µwater) / (µwater – µair) , (1) 
where µwater and µair are respectively the linear attenuation coefficients of water and air. 
Gneveckow et al. have reported that for iron concentrations above ca. 10 mgFe/mltissue 
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the radiodensity exceeds ca. 60 HU [30], which is a level that is distinguishable from, 
for example, breast cancer tumour tissue, which has a radiodensity of ca. 35 ± 20 HU 
[34]. The same authors subsequently reported on clinical studies of 10 prostate cancer 
patients, where radiodensities in the range ca. 150 to 200 HU were recorded for cases 
where the anticipated in situ iron concentration was ca. 55 mgFe/mltissue [2]. 
2.2.3 In vitro, preclinical and clinical measurements of Vd/Vi   
Consequently, despite the complexity of the inter-related physical, chemical and 
material factors that contribute to Vd/Vi  for a given system, progress has been made 
towards understanding and, just as importantly, controlling the interstitial administration 
process. For example, Zhu et al. have conducted some illuminating studies on infusion 
strategies for magnetic fluids, using both in vitro gel phantoms [17], and in vivo murine 
models [18]. They reported that quasi-homogeneous in vivo dispersions (as measured by 
micro-CT) could be repeatably obtained using a syringe pump to provide very slow 
(3 µl/min for 30 min) intratumoural delivery of the agent through a very fine gauge (26 
gauge, 0.26 mm inner diameter) needle [18]. Furthermore, they were able to 
systematically vary the Vd/Vi  dispersion factor in xenograft tumours from 0.77 ± 0.06 at 
the 3 µl/min rate, up to 1.26 ± 0.24 at a faster 5 µl/min rate [18]. 
A similarly slow and controlled infusion strategy is being clinically pioneered 
for the intracranial delivery of drugs to treat brain cancer [19-21]. Convection enhanced 
delivery (CED) involves the surgical placement of a catheter into the tumour, followed 
by infusion of the therapeutic agent into the target over a prolonged period, typically 
several hours. Reported data here include two clinical cases where Gd-DPTA was 
infused into human brain stem lesions, with measured Vd/Vi values of 2.4 and 3.7 [35], 
and preclinical experiments where 14C-labelled albumin was infused into the striatum of 
rats, yielding Vd/Vi values of order 5 [36]. Another aspect of CED that may be of 
particular note in the context of magnetic hyperthermia is that significant effort is being 
directed towards designing novel catheters that minimise or eliminate reflux of the 
infusate back up the catheter/tissue interface track [20, 22]. 
The MagForce team’s approach has been to make multiple-site low-volume 
injections into a variety of tumour types in an effort to achieve quasi-homogeneous 
distribution of their magnetic fluid agent over entire tumours. For example, in one paper 
they report on the case of a prostate cancer patient for whom a total dose of 12.5 ml of 
agent was administered into a 35 ml target volume in the form of 24 depots of ca. 0.5 ml 
each [2]. In that particular case, it is not clear that the approach was successful, given 
that the post-administration CT image shows distinct separation between the 
neighbouring depots [2]. Other cases are more convincing, as seen in the CT scans they 
show for glioblastoma multiformae patients, for which the CT contrast does not 
discernibly vary over the entire tumour volume as treated [3, 37]. The authors note that 
the total injected dosages that were applied in these cases corresponded to ca. 0.3-0.4 ml 
of magnetic fluid per ml of tumour tissue for one set of 22 prostate and cervical cancer  
and soft tissue sarcoma patients [3], and a median dosage of 0.28 ml of magnetic fluid 
per ml of tumour tissue for a set of 66 glioblastoma multiformae patients [37]. If we 
take these figures to be representative of Vi and Vd volumes respectively, this 
corresponds to clinical estimates of mean Vd/Vi values for the magnetic fluid of ca. 2.5-
3.3 in the first instance, and ca. 3.6 in the second instance.  
More individual-patient-specific data is presented in another report from the 
MagForce team, regarding a cohort of patients with non-resectable and pre-treated 
rectal, cervical and ovarian tumours [10]. Under CT-guidance, the administered 
magnetic fluid volumes in this study ranged up to ca. 83% of the tumour volume, with a 
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mean of ca. 41%. The authors noted that at these levels: “instillation of the 
nanoparticles could be performed well and all patients tolerated the procedure without 
side effects” [10]. If we convert these percentages into corresponding Vd/Vi values 
(assuming homogeneous distribution, as was the team’s objective), we obtain a 
minimum of ca. 1.2 and a mean of ca. 2.4.  
To place these values in context, it is perhaps instructive to note that Vd/Vi 
values in the vicinity of 3 are comparable to the figure that one might predict if one 
assumed that the injected fluid infiltrated only the extracellular part of the tissue. We 
can show this by taking, as a rough estimate, the commonly quoted figures for a 70 kg 
male, viz. that ca. 28 litres of the body’s fluid resides within cells, compared to 10.5 
litres in the interstitial extracellular spaces [38]. In this case, if the injected fluid 
displaced all the interstitial fluid in a given volume of tissue, the corresponding Vd/Vi 
would be of order 38.5/10.5 » 3.7. Of course this is not a very precise result, but it is 
perhaps a useful figure for comparative purposes. For example, the Zhu group’s 
reported dispersion factors of Vd/Vi » 0.8-1.3, achieved using very slow infusion-pump-
controlled delivery, and MagForce’s Vd/Vi » 1.2 in one particular pelvic cancer patient, 
might both be considered to be examples of ‘beating’ the intrinsic fluid displacement 
mechanism, while MagForce’s mean values of Vd/Vi » 3.6 in brain cancer tumours 
might considered to be closer to the ‘natural’ level. 
2.3 Regulatory pathways may depend on the administration route 
Another important reason to focus on interstitial administration is that the regulatory 
pathway to clinical translation may be substantially less complex than would be the case 
for intravenous injection, particularly in cases where the injectable fluid might be 
considered to be a medical device. National and international regulatory authorities, 
such as the US Food and Drug Administration (FDA) or the European Medicines 
Agency, set out many detailed criteria against which a given substance must be tested to 
gauge whether it should be treated as a medical device or as a medicinal product, the 
description of which is beyond the scope of this paper. Nevertheless, as a guiding 
principle, a product may be regulated as a medical device if its manufacturer can 
establish that its primary mode of action (PMOA) is physical in nature, and not 
pharmacological, immunological, or metabolic.  
With magnetic hyperthermia agents, it might reasonably be argued that the 
PMOA is a physical mechanism, namely the local generation of heat through the 
transduction of an externally applied time-varying magnetic field into heat-inducing 
magnetisation reversals in magnetic nanoparticles. Furthermore, in the case of 
interstitial administration of such an agent, parallels may be drawn with the PMOAs of 
implantable medical devices, such as the recently approved Magseed® from Endomag 
Ltd (Cambridge, UK), which is a grain-of-rice sized magnetisable steel implant used for 
lesion localisation. In contrast, it is not so obvious how one could make a similar 
argument in the case of the administration route being intravenous.  
In this paper we will proceed under the assumption that the PMOA of the 
interstitially introduced hyperthermia agent is physical, and that as such the intervention 
associated with its use may be considered to be that of a medical device. It should be 
noted, however, that other PMOAs might be envisaged for hyperthermia agents, 
including their designation as drug-device combination products, in which case more 
pharmaceutical-oriented regulatory pathways might need to be adopted.  
We note in passing that irrespective of whether the agent is regulated as a device 
or a drug or a combination product, there are also safety considerations regarding the 
time-varying magnetic field source itself, and regarding the effect of those time-varying 
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fields on the human body. Detailed consideration of this is beyond the scope of the 
current work, but the subject has been addressed elsewhere [13, 39-41]. Similarly, the 
clinical treatment plan for a given patient (which includes the duration and schedule of 
the hyperthermia treatment session or sessions) will have a direct impact on both the 
safety and efficacy of the intervention. Again, detailed discussion of this is beyond the 
scope of this work, and the subject has been reviewed elsewhere [42-45].   
Lastly, it should be noted that with regard to regulatory pathways, the magnetic 
hyperthermia ‘system’ as a whole may in some cases – depending on jurisdiction – be 
taken to include both the introduced hyperthermia agent and the attendant time-varying 
magnetic field source acting together, or as one acting as an accessory to the other. Such 
demarcations have significant implications with regard to the nature of the clinical 
studies that need to be performed to establish their safety for the respective national and 
international regulatory authorities. 
2.4 Adverse effect levels and preclinical-to-clinical scaling depends on the 
administration route 
Regulatory authorities have a responsibility to scrutinise all aspects of the safety of the 
proposed medical intervention, including setting the conditions under which clinical 
studies may be undertaken. In this context, we note that the FDA has published a 
‘guidance for industry’ document in which they describe how one should estimate the 
maximum safe starting dose for therapeutics (or other agents) in initial clinical trials in 
healthy adult volunteers – and that these conditions are quite different for interstitial 
versus intravenous administration [46]. In both cases the safe starting dose in humans is 
estimated from preclinical studies, but the methodology is quite different.  
2.4.1 Preclinical-to-clinical scaling for intravenous administration 
For intravenously administered pharmaceuticals, the FDA stipulates that escalating-dose 
preclinical studies should be performed to establish the ‘no observed adverse effect 
level’ (NOAEL) for a given agent in terms of the mg of administered agent per kg total 
mass of the animal. The FDA notes what it considers to be the sort of findings that can 
be used to determine the animal NOAEL, as follows: overt toxicity (e.g. clinical signs, 
macro- and microscopic lesions); surrogate markers (e.g. serum liver enzyme levels); 
and exaggerated pharmacodynamic effects [46]. However, it is up to the manufacturer 
to decide precisely which tests to undertake for a given agent. 
Once an animal NOAEL has been determined, this is converted to a ‘human 
equivalent dose’ (HED), which is then used to calculate a ‘maximum recommended 
starting dose’ (MRSD) for the initial clinical studies after applying a downscaling factor, 
usually taken to be 10: 
 𝑀𝑅𝑆𝐷%.'.	(mg/kg) = 	𝐻𝐸𝐷i.v.	(mg/kg)	of	the	animal	𝑁𝑂𝐴𝐸𝐿i.v.	(mg/kg)10  , (2) 
where the subscript i.v. denotes intravenous administration.  
The HEDi.v. term is determined from the measured animal NOAELi.v. by 
normalising to body surface area, which is taken to correlate with the species-specific 
metabolic rate [46, 47]. For a given species the normalising factor Km is estimated by 
dividing the average body weight of the species by its corresponding average body 
surface area. For example, for a mouse of body weight 0.021 kg and surface area 
0.007 m2, Kmmouse = 3 kg/m2; while for humans the reference weight is taken to be 60 kg 
and body surface area 1.62 m2, yielding Kmhuman = 37 kg/m2 [46, 47]. The HEDi.v. is then 
calculated as: 
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 𝐻𝐸𝐷%.'.	(mg/kg) = 	Animal	𝑁𝑂𝐴𝐸𝐿i.v.	(mg/kg)	×	Animal	𝐾m	(kg/m2)Human	𝐾m	(kg/m2)   . (3) 
For example: for a murine preclinical model, the HEDi.v. in mg/kg equals the NOAELi.v. 
in mg/kg measured in the mouse, multiplied by a factor Kmmouse / Kmhuman = 0.081.  
2.4.2 Preclinical-to-clinical scaling for interstitial administration 
For interstitial administration of agents, the FDA guidance is that the NOAEL to 
HEDinterstitial conversion may be achieved either by normalising to concentration, or to 
the amount, of the agent at the injection site. For magnetic hyperthermia agents where, 
as discussed above, we know that the local distribution and parameters such as Vd/Vi 
determine the efficacy of the agent, it is clear that from a regulatory perspective we 
should normalise to the local concentration at the injection site: 
 HEDinterstitial (mg/mltissue) = Animal NOAEL (mg/mltissue) , (4) 
where the concentration is calculated as the mass of the injected agent (the magnetic 
nanoparticles) divided by the volume Vd (measured in mltissue) into which the agent is 
dispersed. The MRSD should be downscaled as before: 
 𝑀𝑅𝑆𝐷interstitial	(mg/mltissue) = 	𝐻𝐸𝐷interstitial	(mg/mltissue)	10   . (5) 
The FDA does not provide any particular guidance on how to determine the 
animal NOAEL in the case of interstitial administration, but it is clear that one should 
consider potential local toxicity, as well as systemic toxicity. For the former, it is logical 
to look for indicators such as inflammation and granulation at the injection site, 
alongside the usual systemic toxicology biomarkers such as hematology, clinical 
observation and histopathology [48, 49]. 
2.5 Maximum injection volume depends on the administration route 
Regarding the scaling of preclinical NOAEL results to clinical HED and MRSD values, 
one final point to note is that in addition to the administration route, the selection of 
injection site has a bearing on the injection volume Vi that may be used [50]. This is 
illustrated in Table 1, which shows the Duke University Medical Center’s local 
guidelines for the site-dependent maximum injection volumes permitted in healthy 
mice, rats, rabbits and humans [47]. On inspection one can see clearly that the 
maximum allowable Vi does not scale either with body weight or body surface area. 
This species-dependent variation can be important when one considers which is the 
most suitable animal model to use for a given clinical indication. 
Furthermore, the maximum guideline doses for one site (e.g. subcutaneous 
injections) may be tens or even hundreds of times greater than those for another site 
(e.g. intramuscular or intradermal ones). This rightly reflects the differing physiology 
and anatomy of those sites, and the different species’ respective tolerances to paternal 
administration at those sites; but again it may impact the choice of animal model, and as 
such should be duly considered.   
It is also significant that guidelines such as those in Table 1 are local guidelines, 
falling within the purview of the local ethics and R&D approvals committees, so that 
they may well vary from one institution to the next. For example, the guidelines for the 
US National Cancer Institute in Frederick, MD, although being very similar to those at 
Duke University, nevertheless cite a 4x larger figure for mouse/subcutaneous injections, 
and 3x smaller figure for rat/intramuscular injections [51].  
Lastly, the guidelines in Table 1 refer to injections into healthy tissue. The 
corresponding guidance for intratumoural injections is somewhat less explicit, as the 
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acceptable dose scales with the tumour volume. Giustini et al. report on injecting a 
magnetic hyperthermia fluid into 50-200 mm3 murine adenocarcinoma tumours at a 
ratio of 0.34 µl per mm3 of tumour [52]. Assuming that in this case the magnetic fluid 
dispersed over the entire tumour volume, this corresponds to a Vd/Vi of order 3, which is 
in line with the values discussed above. In humans, intratumoural injection volumes can 
be of similar magnitudes, or larger. Hassenbusch et al., for example, reported a 
pharmaceutical dose escalation study on 40 patients with recurrent malignant glioma 
[53]. In the Vi -escalation part of this study, injection volumes of 25%, 50% and 75% of 
the tumour volumes were trialled, with no adverse events observed at either the 25% or 
the 50% level. The maximally tolerated dose was determined to be 5 ml. 
3. Acceptable dosage limits according to current clinical practice  
Having explored some of the issues associated with the administration route, we turn 
now to the question of what is an acceptable dosage for the interstitial injection of a 
magnetic fluid? Our starting point is to review the dosages that the manufacturers of 
currently available commercial products recommend to clinical users, as those 
manufacturers will certainly have already passed through the animal NOAEL to HED to 
MRSD pathway on their way to commercialisation.  
There are four such products currently available: two of them, Resovist® and 
Feraheme®, are intravenously administered, and are regulated as drugs; the other two, 
Sienna+® and Nanotherm®, are interstitially administered, and are regulated as medical 
devices.  (N.B. The drug/device designation is determined by the mode of action of the 
material, rather than the mode of administration.) All four manufacturers will have had 
to meet stringent regulatory standards as part of their respective accreditation processes, 
and as such the figures quoted in their published instructions for use (IFU) pamphlets1 
may be considered to be reliable indications of the acceptable limits for their product’s 
use, in terms of both tolerance and efficacy. 
3.1 Review of recommended dosages for clinically approved materials 
In the 1990s and 2000s Resovist® was manufactured in Europe by Schering AG (Berlin, 
Germany) and in Asia by Fujifilm RI Pharma (Tokyo, Japan), but since 2010 it has been 
made and used exclusively in Japan. Resovist® – also known as ‘ferucarbotran’ - is a 
medicinal product intended for intravenous use as an MRI contrast agent for liver 
lesions. It is supplied in 0.9 ml or 1.4 ml syringes and comprises dextran-coated multi-
core iron oxide nanoparticles. According to its Schering-era IFU [54]:  
The amount of iron in the recommended dose of Resovist® (0.9 ml in patients < 
60 kg body weight, 1.4 ml in patients ≥ 60 kg body weight, corresponding to 5.8 –
12.9 µmol Fe/kg by weight) is equivalent to about 1% of normal whole-body iron 
content. This is equivalent to the normal dietary intake of iron in 2-3 days. 
Administration of this amount of iron will result in transient changes in serum iron, 
ferritin, and iron-binding capacity, but there is no danger of iron overload.  
Resovist® contains 28 mgFe/ml, so the maximum recommended dose of 1.4 ml in a 
60 kg human corresponds to 0.65 mgFe/kg, although, somewhat curiously, the 
12.9 µmolFe/kg limit quoted in the IFU corresponds to the slightly higher figure of 
0.72 mgFe/kg. Interestingly, another version of the IFU, published in 2002 by 
distributors Agis Commercial Agencies Ltd [55], contained the following note: 
                                                
1 For convenience, copies of all the IFUs referenced in this paper are included in the 
Supplementary Information, section S1. 
Accepted for publication in the International Journal of Hyperthermia 10 
The maximum dose tested in humans, 0.08 ml Resovist® (equivalent to 2.24 mg 
Fe) per kg body weight, was well tolerated.  
which indicates that intravenous doses up to 2.24 mgFe/kg (or 40 µmolFe/kg ) have been 
tested in humans with no adverse effects. 
Feraheme® – also known as ‘ferumoxytol’ – is made by AMAG 
Pharmaceuticals (Waltham, MA, USA), and is a medicinal product intended for 
intravenous use as treatment of iron deficiency anemia in adult patients with chronic 
kidney disease. It comprises carbohydrate coated iron oxide nanoparticles, and is 
supplied in 17 ml vials at a concentration of 30 mgFe/ml. According to its IFU [56]:  
The recommended dose of Feraheme® is an initial 510 mg dose followed by a 
second 510 mg dose 3 to 8 days later. Administer Feraheme® as an intravenous 
infusion in 50-200 mL 0.9% Sodium Chloride Injection, USP or 5% Dextrose 
Injection, USP over at least 15 minutes.2  
Assuming 60 kg as an adult human’s minimum weight, the 510 mg dose corresponds to 
8.5 mgFe/kg, which is quite a lot higher than the Resovist® dose. That said, elsewhere in 
the IFU the manufacturers describe some preclinical models as follows:  
Administration of ferumoxytol during organogenesis, at doses of 31.6 mg 
Fe/kg/day in rats and 16.5 mg Fe/kg/day in rabbits, did not result in maternal or 
fetal effects. These doses are approximately 2 times the estimated human daily 
dose based on body surface area.  
Assuming that they followed the FDA’s guidelines for calculating HEDs from animal 
models [46] we can estimate what AMAG mean by ‘the estimated human daily dose’. 
For a rat the conversion factor is 6.2, while for a rabbit it is 3.1, so that it is apparent 
that AMAG is referring here to a safe-level human daily dose of ca. 2.6 mgFe/kg. This 
figure is close to the Day 0 dose divided by 3, which is understandable as AMAG 
advise that the second dose should be on Day 3 to Day 8. Thus, it is clear that AMAG 
advise that a bolus injection of up to 8.5 mgFe/kg is safe, so long as any repeat of that 
bolus injection comes at least 3 days later. 
Sienna+® is made by Endomag Ltd (Cambridge, UK) and is a medical device 
intended for interstitial use as a magnetic tracer as part of a system to mark and locate 
lymph nodes prior to surgical removal. It is supplied in 2.2 ml vials and comprises 
dextran-coated iron oxide nanoparticles. Each ml of Sienna+® contains 28 mg Fe. 
According to its IFU [57]:  
Recommended dose is 2 ml with the equivalent iron content of 55 mg ± 4 mg per 
dose. […] For Breast: Draw 2 ml of Sienna+® [and] 3 ml of 0.9% sterile saline 
into the syringe [into a syringe and administer] by subcutaneous injection into 
either subareolar or peritumoural interstitial tissue, and follow with 5 minutes 
vigorous massage at the injection site. […] For other indications: Draw 2 ml of 
Sienna+® [into a syringe and administer] by subcutaneous injection into 
peritumoural interstitial tissue and, where appropriate, follow with 5 minutes 
massage at the injection site.  
From this it is clear that the maximum recommended dose is 2 ml or 56 mgFe, delivered 
directly into the tissue. If this was given to a 60 kg adult the effective dose would be 
0.93 mgFe/kg, although the more relevant parameter given the interstitial administration 
route is the local Fe concentration at the injection site, in mgFe/mltissue. Assuming, as per 
the MagForce data that was discussed in Section 2.2.3, a Vd/Vi dispersion factor of 2.4 – 
which we choose as being representative of that which has been clinically achieved 
                                                
2 ‘USP’ here refers to substances defined in the United States Pharmacopeia.  
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following intratumoural injection [10] – we can speculate that the maximum injected in-
tissue concentration may be 56 mgFe in 4.8 mltissue, or ca. 12 mgFe/mltissue. Note that this 
is for the non-breast indications; and that in the case of breast cancer, the administered 
concentration is lower due to the additional 3 ml of saline, taking the maximum in-
tissue concentration down to ca. 5 mgFe/mltissue. Note also that it is likely that the Vd/Vi 
dispersion factor in peritumoural tissue will be different from the 2.4 figure used here, 
which was measured for tumour tissue.  
Nanotherm® is made by MagForce AG (Berlin, Germany), and is an 
aminosilane-coated iron oxide nanoparticle ferrofluid. At the time of writing, no official 
company-issued IFUs were found online, but several scientific publications are 
available, including a 2011 paper on the clinical treatment of recurrent glioblastoma 
multiformae, a type of brain cancer, that contained the following passage [37]:  
The magnetic fluid MFL AS1 (NanoTherm AS1; MagForce Nanotechnologies), an 
aqueous dispersion of superparamagnetic nanoparticles with an iron concentration 
of 112 mg/ml, served as the energy transducer. […] The median amount of 
magnetic fluid injected was 4.5 ml (range 0.5–11.6 ml), corresponding to a median 
dosage of 0.28 ml of magnetic fluid per cm3 of tumor volume.  
From this we deduce that the maximum administered dose in the study was 11.6 ml or 
1300 mgFe, delivered directly into the brain tissue – which is a substantial amount. If we 
again consider a representative Vd/Vi dispersion factor of 2.4, then, given that the 
injected fluid contained 112 mgFe/ml, the maximum in-tissue concentration in all cases 
was ca. 47 mgFe/mltissue. This figure appears to be internally consistent, given that the 
value quoted by MagForce as the median dosage of the treatment, viz. 0.28 ml of 
Nanotherm® per ml of tumor tissue, equates to ca. 31 mgFe/mltissue. 
3.2 Summary and implications of current clinical practice 
The two intravenously introduced iron-oxide-based magnetic fluids, Resovist® and 
Feraheme®, have maximum indicated or reported doses of ca. 2.2 mgFe/kg and 
8.5 mgFe/kg, respectively, with the proviso that Feraheme® should not be administered 
more frequently than once every three days. If administered daily, it is separately 
reported by AMAG that up to ca. 2.6 mgFe/kg of Feraheme® is safe and well tolerated.  
For the two interstitially introduced fluids, Sienna+® and Nanotherm®, the most 
appropriate metric is the magnetic particle concentration at the injection site. Although 
neither manufacturer states the mgFe/mltissue values explicitly, we can make educated 
guesses as to their values, subject to assumptions regarding the dispersion 
characteristics of the injected fluid. Within these constraints, for Sienna+® we estimate 
that the recommended dose equates to at most ca. 12 mgFe/mltissue, while the median and 
maximum reported Nanotherm® doses are ca. 31 mgFe/mltissue and 47 mgFe/mltissue 
respectively. Regarding the latter figure, given the wide spread reported in the 
MagForce studies, it seems prudent to regard this as an outlier; in which case a more 
representative value for the maximum level should be closer to the median – we suggest 
a value of ca. 40 mgFe/mltissue. 
From this we can draw some indicative conclusions regarding the dose limits 
that might be kept in mind when developing Fe-based magnetic fluids for therapeutic 
benefit in humans, as follows:  
(1) that for intravenous administration there are clinical products in use today for 
which total Fe dosage administered at any one time may be as high as 8.5 mgFe 
per kg of body weight; and for which the total daily Fe dosage may be as high as 
2.5 mgFe per kg of body weight; and 
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(2) that for interstitial administration, assuming a dispersion factor of Vd/Vi = 2.4, 
there are clinical products in use today for which the local Fe dose is up to 
12 mgFe/mltissue per site for subcutaneous injections and up to 40 mgFe/mltissue per 
site for intratumoural injections. 
The limits in (1) are derived from the published data on Feraheme® for the one-off dose, 
and on both Feraheme® and Resovist® for the daily dose; and those in (2) are derived 
from the published data on Sienna+® (subcutaneous) and Nanotherm® (intratumoural) 
respectively. 
It should be emphasised that these values are specific to the materials in 
question, and their intended uses. For example, Feraheme® has been formulated to be 
well tolerated in the blood stream, and rapidly taken up in the liver and spleen, and 
therefore its intravenous dosage limit may be higher than that of other formulations of 
similar products. On the other hand, the intended use for Sienna+® is that it should be 
transported away from the injection site through the lymphatic system, which is 
arguably not relevant to the situation one might foresee for a magnetic hyperthermia 
agent. In this context the dose limit associated with Nanotherm® is the most relevant for 
researchers in the field, although again it is likely to be formulation dependent – 
particularly with respect to the Vd/Vi dispersion factor. That said, the ‘up to 
40 mgFe/mltissue per site for intratumoural injections’ limit has clearly been clinically 
tested, and as such is a useful touchstone for the development of alternative 
hyperthermia agents and the designing of preclinical and first-in-man clinical safety and 
dose-escalation studies. 
4. Design of preclinical studies of intratumoural magnetic hyperthermia  
We return now to the issue of how to design for the transition from preclinical to 
clinical studies of hyperthermia. We illustrate the process here with respect to a 
prospective intratumoural administration route, but similar steps will need to be taken 
for whichever injection site is relevant for a given therapeutic indication. 
4.1 Establish dose limits based on the intended clinical use 
Let us imagine, for illustrative purposes, that we have formulated a magnetic 
hyperthermia agent with an intratumoural Vd/Vi dispersion factor of 2.4, and that the 
iron concentration of the agent can be varied continuously up to, say, 120 mgFe/ml. 
(N.B. We are ignoring here the problems associated with the high viscosity of highly 
concentrated fluids.) Using the clinical experience of the Nanotherm® intratumoural 
injections, we can anticipate an in situ dosage limit of Co = 40 mgFe/mltissue per site of 
injection, which – given that Vd/Vi = 2.4 – means that the concentration of the fluid 
should not exceed (Vd/Vi) ´ Co = 96 mgFe/ml. 
Next we must consider the degree of retention of the injected agent at the 
tumour site. There are many factors that contribute to this, including the formulation of 
the agent, the injection method employed (e.g. multiple or single doses; infusion or 
bolus; speed of withdrawal of the needle), the character of the tumour and its 
surrounding tissue, and the kinetics of both the initial dispersion of the agent and its 
subsequent clearance, over time, by the reticuloendothelial system. Bazan-Peregrino et 
al. have reported on a number of the non-formulation factors that affect retention, 
showing for one particular tumour type in a murine model that the injection method 
could change the retention from ca. 80% down to ca. 40% of the administered dose, and 
that changing to another tumour type brought the retention up to ca. 95% [58]. Their 
injectate was an adenovirus, and their measurements were recorded 30 minutes after 
Accepted for publication in the International Journal of Hyperthermia 13 
injection, which they inherently considered to be sufficient to achieve homeostasis. We 
might reasonably expect that a magnetic fluid injectate might be formulated to have a 
similar degree of retention at a similar timepoint. Regarding the rate of macrophage-
mediated clearance, MagForce have reported clinical CT imaging data for a prostate 
cancer patient that clearly shows substantial retention of intratumourally administered 
magnetic nanoparticles a full six weeks after the injection date [2]. In this respect we 
can therefore reasonably expect that formulations can be found that allow for prolonged 
material retention at the injection site.  
Regarding the character of the tumour and its surrounding tissue, the Bazan-
Peregrino et al. data shows that different tumours types have different retention 
characteristics. It should also be noted that the intratumoural injection site itself may 
have an effect: e.g. whether the injectate is encountering the stroma or the parenchyma 
of the tumour, or the proliferative versus quiescent versus necrotic regions of the 
tumour. Furthermore, tumours often have different microenvironments (including 
elevated interstitial pressures, hypoxia and acidosis) than do the surrounding tissues, 
and different tissues themselves have different perfusion and clearance characteristics. 
All of these biological factors represent challenges to successful delivery and retention 
[59, 60]. While this is clearly difficult and unpredictable, nevertheless it is also clearly 
surmountable, as the MagForce experience shows, given the right formulation and the 
right mode of (interstitial) administration. 
Let us therefore proceed, and assume, for our hypothetical clinical indication, 
that we expect the retention of the magnetic agent to be ‘good’, at ℛ = 85%, so that only 
(1 – ℛ) = 15% of the dose is lost via perfusion into the bloodstream. Let us further 
assume that the formulation of our agent, albeit not explicitly intended for intravenous 
use, is also ‘good’, and that the maximum allowable systemic dose is a factor ℱ = 85% 
of the daily intravenous administration limit (𝒟M = 2.5 mgFe/kg) established for 
Feraheme® and Resovist®.3 We can then estimate the maximum allowable intratumoural 
injected dose limit, as per the formula:  
 𝒟NOP = (ℱ ´ 𝒟M) / (1 – 	ℛ) , (6) 
to be 𝒟NOP = 14.2 mgFe/kg for this ‘good’ retention and formulation scenario. It should 
be noted that 𝒟NOP will vary between one agent and another. For example, an agent 
with a relatively ‘poor’ performance scenario of low retention (ℛ = 0.5) and low 
systemic tolerance (ℱ = 0.5) would be limited to a 𝒟NOP = 2.5 mgFe/kg. In an ‘excellent’ 
scenario, with say ℛ = 0.95 and ℱ = 1.00, the maximum would be much higher, with 𝒟NOP = 50 mgFe/kg. We note in passing that MagForce have reported on clinical studies 
that have involved the injection of magnetic fluids into the human prostate of doses in 
the range 1.1 to 1.5 grams of iron [61], which, assuming that their subjects had total 
body masses up to say 90 kg, would fall within the expected 𝒟NOP limits of a ‘very 
good’ product with both ℛ and ℱ values of order 87%.  
Equation (6) embodies the notion that despite the agent being formulated with 
interstitial administration in mind, we still need to consider its safety with regard to 
systemic delivery. This also impacts on preclinical studies, in that it indicates that dose-
escalation studies should be undertaken to establish or verify intravenous NOAELs and 
HEDs – just as for systemic agents – using the FDA’s body surface area factors to scale 
between the preclinical and clinical cases. For example in a murine preclinical model  
                                                
3 Note that it could be argued that the one-off intravenous administration limit of 𝒟M = 
8.5 mgFe/kg that has been established for Feraheme® might be equally suitable here, but that for 
the purpose of illustration we have chosen to use the lower, daily administration value. 
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the Feraheme® and Resovist® daily intravenous dose level of 𝒟M = 2.5 mgFe/kghuman 
would correspond, using Equation (3) and the scaling factor Kmhuman / Kmmouse = 12.3, to 
an intravenous NOAEL dose limit of 𝒟Mmouse = 30.8 mgFe/kgmouse. Applying this to the 
‘poor’, ‘good’ and ‘excellent’ retention and tolerance scenarios discussed for man, and 
assuming a mouse of body mass 20 g, the corresponding 𝒟NOPmouse estimates are ca. 0.6, 
3.5 and 12.3 mgFe respectively.  
With these figures in mind, we note from the literature that research groups 
around the world are adopting a wide range of different dosing protocols in their mouse 
models. Some apply less than 1 mgFe per mouse [62, 63], while others use ca. 4 mgFe 
per mouse [64]. The largest doses we found were ca. 25 mgFe per mouse, as used by the 
Zhu group [18, 31]. At a glance these seem high doses, although it should be noted that 
they were achieved using that group’s controlled infusion strategy, so that near 100% 
interstitial retention might be assumed. Indeed, putting ℛ = 0.98 and ℱ = 1.00 into 
Equation (6) one obtains 𝒟NOPmouse = 25 mgFe. 
4.2 Consider formulation with reference to projected clinical efficacy 
The next step is to model the efficacy of the projected treatment, in order to establish 
the functional bounds within which the magnetic heating agent will need to operate. The 
efficacy depends on both the physical properties of the agent (in particular the magnetic 
heating characteristics of the magnetic nanoparticles) and the physical properties of the 
time-varying activation field (in particular its amplitude H and frequency f).  
Given these parameters, various theoretical models exist that describe the 
expected biophysical heat flows in different conditions, which we can use to predict in 
silico the temperature increase ΔT at and around the injection site. Surveying a selection 
of recent publications on such models in the field of magnetic hyperthermia [65-72], 
two things are apparent: (i) that the methods that different authors adopt to address the 
problem are many and varied, and can be mathematically very complex; and (ii) they all 
take as their starting point the ‘Pennes equation’:      
 𝜌𝐶 𝜕𝑇𝜕𝑡 = 𝑘∇X𝑇 +	𝜌Z𝐶Z𝜔Z 𝑇Z − 𝑇 +	𝑄N^_ +	𝑄^P_   , (7) 
where 𝜌, 𝐶 and 𝑇 are the density, specific heat capacity and temperature of the tissue; 𝜌Z, 𝐶Z and 𝑇Z are the corresponding parameters for blood; 𝑘 is the thermal conductivity 
of the tissue; 𝜔Z is the blood flow rate per unit tissue volume; and 𝑄N^_ and 𝑄^P_ are 
heat generation rates due to tissue metabolism and external sources respectively. The 
Pennes equation is named after an American neurologist who in 1948 was the first to 
introduce the terms representing the heat transfer due to perfusion 𝜌Z𝐶Z𝜔Z 𝑇Z − 𝑇  and 
metabolism 𝑄N^_ to the classical heat equation [73]. The external power dissipation 
term 𝑄^P_ is an additional term which in the current context equates to the heating 
through magnetic hyperthermia, but which more generally can refer to any non-
metabolic heat source. 
In this paper it is not our intention to critique the various available bioheat 
models for magnetic heating, nor do we wish to introduce a comprehensive but complex 
model that covers multiple scenarios such as time-dependent effects, thermally-varying 
perfusion, or variations in metabolic rate between tumour tissue and healthy tissue. 
Such considerations have been covered in other works, including those already cited 
[65-72]. Instead, we present here a simple analytical model that enables a ‘first 
approximation’ predictive step to be taken in the translation of magnetic hyperthermia, 
directed towards treatment planning. This is the magnetic thermotherapy equivalent of 
the ‘dose-response’ therapeutic paradigm: i.e. that it is incumbent on the practitioner to 
understand and be able to predict the expected response to a given treatment dose. 
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We therefore consider here a simple analytical model, in which the effects of 
both perfusion and metabolism are neglected, and in which it is assumed that an 
equilibrium state has been achieved, so that 𝜕𝑇 𝜕𝑡 = 0. The model is based on that of 
Andrä et al. [74], who considered the temperature distribution within and surrounding a 
spherical volume of radius R containing a uniform distribution of magnetic nanoparticle 
heat sources that in effect acts as a composite heat source. Although Andrä et al. 
describe in some detail the time evolution of the heat distribution around the source, 
they also showed that in the equilibrium state – achieved after prolonged exposure – the 
temperature distribution as a function of distance r from the centre of the sphere could 
be expressed analytically as: 
 ∆𝑇 𝑟 = 	𝑃𝑅26𝑘1 	 1 − 𝑟2𝑅2 + 2 𝑘1𝑘2      for   r  <  R   , (8a) 
 ∆𝑇 𝑟 = 	𝑃𝑅23𝑘2 	𝑅𝑟      for   r  ≥  R   , (8b) 
where 𝑃 is the power density (in W/m3composite) being delivered to the sphere, and 𝑘e and 𝑘X are the thermal conductivities (in W/Km) of the composite core and the surrounding 
medium. This distribution is plotted in Figure 1 for various realistically achievable 
values of 𝑘e 𝑘X, from which it can be seen that the temperature distribution is largely 
unaffected by such changes, and that the more important determinant of the observed ΔT 
is the power density P. 
Although this simplified model is clearly unrealistic in that it ignores the 
question of how the body’s thermoregulatory system will respond to the local 
deposition of thermal energy, it can be inferred from the literature that it is in fact a 
reasonably good approximation. Cheng and Liu describe in detail a numerical model of 
thermal dissipation in spherical breast cancer tumours and surrounding healthy tissue, 
using the full Pennes equation, and including independent perfusion and metabolic heat 
generation terms for the tumour and healthy tissues respectively [65]. They compare 
their results directly with the Andrä et al. model, and show that the results overlap when 
they set the perfusion and metabolism terms in their model to zero. They then also 
compare the time dependence of the predicted ∆𝑇 values at the origin (r = 0) and at the 
boundary of the magnetic-particle infused spherical region (r = R) for both the zero 
perfusion and metabolism model, and their fully-implemented breast cancer model. The 
difference between the two models is significant, viz. a ca. 15% decrease in the ∆𝑇 
values at both the origin and at the boundary after prolonged (t ≳ 250 s) exposure to the 
magnetic heat source [65]. (For further details, see the Supplementary Information, 
section S2.) Nevertheless, we consider that the model expressed in Equation (8) is a 
reasonable first approximation to the temperature distribution that may be achievable in 
vivo, albeit that depending on the physiological characteristics of the target site in the 
body, it will almost certainly be an over-estimate of the actual sustainable values. We 
will return to this point later (see Section 5). 
In passing, it may be interesting to note that Figure 1 illustrates an often-
neglected aspect of magnetic hyperthermia, namely the degree to which the tissue 
surrounding the focal point of the thermal treatment is subject to elevated temperatures. 
For example, if one is intending to heat a 1 cm3 tumour by ΔT ≥ 6 K for therapeutic 
hyperthermia, Figure 1 shows that a sphere of volume 8 cm3 will be heated by ΔT ≥ 
3 K. This is not particularly surprising or unusual – it is after all a natural consequence 
of the relatively gradual 1/r drop-off in Equation 7(b), which persists even in perfused 
tissue [65] – but it is something to keep in mind for interventions such as hyperthermia 
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where prolonged exposure is anticipated. (The situation is likely to be different in the 
case of therapeutic thermoablation, where the intended ΔT ≥ 23 K treatment is more 
transient, so that the equilibrium state is not reached.) 
The power density P delivered into the composite is related to the heating 
characteristics of the magnetic particles, through either the specific loss power (SLP, 
typically reported in W/gFe) or the intrinsic loss power (ILP = SLP/H2f, measured in 
nHm2/kgFe) parameters. Thus: 
 𝑃 = 	𝑆𝐿𝑃	𝑚Fe𝑉d = 𝐼𝐿𝑃	𝐻2	𝑓	𝑚Fe𝑉d    , (9) 
where mFe is the mass of iron contained within the magnetic nanoparticles, and we use 
Vd = 
mn π R3 to denote the volume of the composite sphere in the model, and to draw a 
parallel with the Vd/Vi dispersion factor we have discussed previously. 
We should note here that the ILP parameter is strictly only valid in the low-field 
linear-magnetic-susceptibility activation regime, where the SLP parameter varies 
linearly as a function of frequency f and quadratically as a function of field amplitude H 
[13, 75]. ‘Low-field’ in this context corresponds to the experimentally determined 
value, for iron-oxide nanoparticles, of H ≲ 5 kA/m [75-77]. This is also a field 
amplitude that has been clinically shown to be tolerable (i.e. not producing any 
noticeable adverse effects such as nerve stimulation or non-specific heating of tissue) 
for at least an hour of continuous application [61], and which has separately been 
theoretically predicted to be a limit below which stimulation is not possible, irrespective 
of rise time, frequency or slew rate [78]. 
It is convenient to rearrange Equations (8) and (9) into a form that highlights the 
role of the most easily adjusted parameters of the agent, namely the iron concentration c 
and the injection volume Vi, in determining the achievable ΔT(r) distributions. If we 
focus on the temperature rise at the interface between the magnetic particle impregnated 
core and the surrounding medium, ΔT(r = R) = ΔTR, and make the substitutions c = 
mFe/Vi and v = Vd/Vi, it is straightforward to show that: 
 Δ𝑇q 	= 		 48𝜋X𝑣 vwx 	 𝐼𝐿𝑃	𝐻2	𝑓	𝑘2 	𝑐	𝑉z{x   , (10) 
which can be rearranged to give: 
 𝑐	 = 		 48𝜋X𝑣 wx 	 𝑘2𝐼𝐿𝑃	𝐻2	𝑓 	Δ𝑇q	𝑉zv{x   . (11) 
The factors in brackets are constant for a given agent formulation and a given activation 
field system, so that Equation (10) can be used to plot a series of ΔTR isotherms in the 
Vi-c plane. This is illustrated in Figure 2 for a model scenario wherein the magnetic 
hyperthermia agent has an ILP = 3.0 nHm2/kgFe, a level that has been reported 
previously in several commercially available magnetic fluids [79]; a dispersion factor v 
= 2.4, in line with the values reported for the MagForce clinical studies on a variety of 
different tumours [10]; and an activation field of amplitude H = 5 kA/m and frequency f 
= 300 kHz, which are values that are considered to be acceptable and achievable in a 
clinical system [13].  
The only other parameter needed to generate Figure 2 is the thermal 
conductivity 𝑘X of the tissue surrounding the injection site. This can vary significantly 
depending on where in the body that site is. For example, according to the IT’IS 
Foundation’s database of tissue properties [80], the human brain, liver, pancreas and 
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prostate gland all have conductivities at 37 °C of order 0.52 W/Km, and the figure for 
blood is similar; but the conductivity of human fat is less, at ca. 0.21 W/Km. Other 
tissues lie between these values, for example connective tissue, at ca. 0.39 W/Km, and 
skin, at ca. 0.37 W/Km; and the breast gland and cortical bone, both of which lie at 
ca. 0.32 W/Km. In Figure 2 we have assumed a value of 𝑘X = 0.52 W/Km. 
Nevertheless, Figure 2 is informative in that it allows us to quickly establish – at 
least in broad terms – the formulation and addressable tumour parameters that will 
determine whether a given target is treatable. For example, to achieve a hyperthermia-
threshold temperature rise of ΔTR = 6 K, then if c = 20 mgFe/mlfluid, Vi must equal or 
exceed 0.61 mlfluid (the point marked A on the figure), which, given that v = 2.4, means 
that the minimum treatable tumour size is 1.5 mltissue. If, in contrast, c = 60 mgFe/mlfluid, 
Vi must equal or exceed 0.12 mlfluid (point B), and the minimum treatable tumour size is 
now much smaller, at 0.29 mltissue. It is also immediately apparent that both points A and 
B fall within the shaded region in Figure 2. That region is important as it encompasses 
the acceptable dose limits for the treatment: the upper limit at c = 96 mgFe/mlfluid 
determined from the 40 mgFe/mltissue limit and the dispersion factor v = 2.4; and the 
other limit being those points for which the product Vi.c = 850 mgFe. As such, both of 
the treatment scenarios, represented by the points A and B, are allowable in terms of the 
material loading of the local tissue and of the body as a whole. 
Lastly, it is perhaps useful to note the parametric correlations that are apparent 
in Equations (10) and (11). For example, c is inversely proportional to the ILP, which 
means that if one develops an agent #2 which has twice the heating capacity as an agent 
#1 (ILP2 = 2ILP1), then one could achieve the same heating effect with a formulation at 
half the concentration (c2 = c1/2), if all else was unchanged. Alternatively, if one wanted 
to achieve twice as much heat generation (Δ𝑇qX = Δ𝑇qe), this could be achieved by 
doubling the concentration (c2 = 2c1), if all else was unchanged. 
4.3 Translate to the appropriate preclinical model 
The final step is to translate the projected clinical treatment – with the formulation and 
dose levels determined for a given heating agent and target using a theoretical scenario 
such as the one discussed above – into an appropriate corresponding preclinical model. 
This is, however, not always entirely straightforward.  
One aspect is that there are numerous instrumental and experimental differences 
between preclinical and clinical studies, that need to be understood and managed. These 
include eddy current effects, which are often more evident in larger animals and in man, 
where large-diameter coil geometries may be used, for which the induced surface 
currents (which scale with the square of the coil radius) are larger [81]; and non-specific 
peripheral heating effects due to resistive heating of the field-generating coils, which 
generally affect small animals more [82]. Similarly, the need to maintain 
thermoregulation and maintain core temperatures in preclinical models even when the 
animals are under anaesthetic, is a major challenge [83, 84]. This is especially important 
in small animals where the loss of heat through the skin is much faster than it is in 
larger animals or man. 
However, even in the case that all such experimental differences have been 
identified and overcome, there are still fundamental challenges that may come into play. 
We illustrate this by assuming that our goal is to translate the human treatment scenario 
represented by points A and B in Figure 2 onto a mouse model, as shown in Figure 3. 
Since we have not changed the properties of the agent, the ILP parameter is the same. If 
we have an excellent tissue model – for example if we are using xenografted human 
tumours in immunosuppressed mice – we might broadly assume that the dispersion 
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factor v and the thermal conductivity 𝑘X will also be the same as in the clinical case. 
Then, for a given activation field H and frequency f, the Vi-c plane plots of ΔTR 
isotherms, as calculated using Equation (7), will be identical to the clinical case – see 
Figure 3. What is very different, though, is the acceptable dose region – the shaded 
region in Figure 3 – with respect to the allowable whole body dose, which for the 20 g 
mouse is Vi.c = 3.5 mgFe, rather than the 850 mgFe in a 60 kg human.4 This has the 
major consequence that now the treatment scenarios A and B fall well outside    
maximum allowable dose region for the mouse, making the experiment ethically 
impossible to perform. 
However, there is an alternative. That is: to alter the activation field parameters 
to bring the treatment points within the allowable region. This is illustrated in Figure 3 
for points A¢ and B¢, which lie on the ΔTR = 6 K isotherm for the case that H ¢ = 10 
kA/m and f ¢ = 1 MHz. Although these are field parameters that are well beyond those 
acceptable in a human, they are certainly achievable and acceptable in a mouse model. 
Furthermore, by carefully choosing the H ¢ and f ¢ parameters, the injection volumes Vi 
required for the experimental treatments may be tailored to the animal model tumour 
volumes, in accordance with the dispersion factor v.  
To our knowledge this is not an animal model design strategy that has yet been 
explored for hyperthermia studies, but in principle it looks to be a well-defined 
approach that has the benefit of focusing on equating the thermal load per tumour from 
one animal to the next. 
5. Discussion 
In this paper we have set out to comment on the practicalities of designing for the 
transition from preclinical to clinical studies of magnetic hyperthermia. Perhaps 
unsurprisingly, we have found that the best way to do this has been to first think 
carefully about the intended clinical intervention that constitutes the ultimate goal of the 
research, and to work backwards from that point to consider which is the best 
preclinical model to adopt en route to that goal.  
We first addressed the question of administration route. In our opinion the 
interstitial route is best suited to early clinical translation in magnetic hyperthermia, 
primarily because of the relative simplicity of the required formulation of the agent 
(which does not need to be explicitly designed to evade the body’s reticuloendothelial 
system, as is the case for intravenous agents), and the ease with which substantial local 
concentrations of magnetic nanoparticles can be deposited at a target site. That said, an 
important determinant for efficacy is the in situ dispersion factor, v = Vd/Vi , where Vd is 
the tissue volume throughout which the injected material is dispersed, and Vi is the 
volume of fluid injected. Values in the range v = 2 to 5 have been reported. Depending 
on the injection site it may also be important to consider peripheral or accidental 
injection into the bloodstream, so that even though the intended route is interstitial, 
there may be some fraction of the agent that is delivered intravenously. 
We have reviewed the ethical, safety and regulatory aspects of the interstitial 
versus the intravenous route, and in particular the way in which preclinical-to-clinical 
dose scaling depends on the administration route. It is clear (as per the US Food and 
Drug Administration’s 2005 guidance for industry) that whereas for intravenous 
                                                
4 Note that this is for the assumed ‘good’ agent formulation scenario of retention (ℛ = 0.85) and 
systemic tolerance (ℱ = 0.85), and that in general the allowable whole body doses will vary 
between different formulations of agent. 
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injection it is expected that dose scaling should be done by normalising to body surface 
area (on the basis that this correlates with species-specific metabolic rates), for 
interstitial injection the normalisation is made with respect to the local concentration of 
the agent at the injection site. It is also notable that the maximum allowable injection 
volume is both species-dependent and site-dependent, and governed by institutional-
level rather than national or international standards; and that for intratumoural injections 
a volume percentage approach (typically Vi » 33% Vtumour) is commonly adopted. 
We have benchmarked the intravenous and interstitial clinical dosage limits of 
four commercially available magnetic fluids, viz. the MRI contrast agent Resovist®, the 
iron replacement agent Feraheme®, the sentinel node detection agent Sienna+®, and the 
magnetic thermoablation agent Nanotherm®. This has led us to propose the following 
potentially useful rules-of-thumb: 
• that for intravenous administration there are clinical products in use today for 
which total Fe dosage administered at any one time may be as high as 8.5 mgFe 
per kg of body weight; and for which the total daily Fe dosage may be as high as 
2.5 mgFe per kg of body weight; and 
• that for interstitial administration there are clinical products in use today for 
which the local Fe dose is up to 12 mgFe/mltissue per site for subcutaneous 
injections and up to 40 mgFe/mltissue per site for intratumoural injections. 
We should treat these figures with caution: they are indicative only, and that they may 
even be mutually exclusive. The intravenous limits are derived from published data on 
Feraheme® for one-off doses, and on both Feraheme® and Resovist® for the daily doses; 
and the interstitial limits are derived from data on Sienna+® for subcutaneous injection 
and Nanotherm® for intratumoural injection. These are four quite different materials, 
with most likely quite different biodistribution and biocompatibility characteristics. 
Even so, we think that it is useful to have such figures at hand, if only to give some 
sense of the range of possibilities that might be available for any new formulations that 
might be explored. 
We have illustrated the process of designing for the transition from preclinical to 
clinical studies for the hypothetical case of an intratumoural hyperthermia agent with a 
given set of assumed material properties for the agent (viz. its heating capacity) and the 
injection site (viz. the tissue dispersion factor and thermal conductivity). As part of this 
we have shown – as embodied in Equation (6) – that two key parameters to note are the 
assumed degree of retention ℛ of the agent at the injection site, and its systemic 
tolerance factor ℱ (relative to the safe intravenous dosing limit 𝒟M established from 
other agents), as these both have a direct bearing on the study design. In Figures 2 and 3 
we illustrated the case for an agent with good (85%) retention and tolerance factors, and 
took 𝒟M = 2.5 mgFe/kg (i.e. the daily intravenous dose limit of Feraheme® and 
Resovist®), which led to the estimation that the maximum total dosages should not 
exceed either 850 mgFe in a 60 kg human or 3.5 mgFe in a 20 g mouse. However, these 
limits could be set higher if the formulation of the agent warrants it, and the ℛ and ℱ 
factors are closer to one. Also, depending on the intended use of the agent, an argument 
could be made that the 𝒟M should be closer to the 8.5 mgFe/kg limit established for one-
off doses of Feraheme®.  
Lastly, we have shown how these dosage limits can be used (alongside a simple 
theoretical model of thermal transfer from a sphere containing a homogeneous 
distribution of magnetic nanoparticles in the presence of an activating field of amplitude 
H and frequency f ) to explore the clinical efficacy of any given proposed therapy as a 
function of the hypothetical formulation of the agent. We have found a simple analytical 
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model – as formulated in Equations (8) and (10), and as displayed in Figures (2) and (3) 
– to be a useful tool to help visualise the design parameter space, and to help to make 
the transition between clinical and preclinical study requirements.  
There is, however, one final matter that we have not fully addressed, which is 
the question of how good or how bad the zero perfusion, zero metabolism model of 
Equations (8) and (10) really is, when it comes to predicting actual heating scenarios in 
vivo. It is not particularly easy to make a definitive assessment of this, as there are very 
few clinical or preclinical studies for which the requisite data is available in sufficient 
detail to enable point-by-point comparisons to be made. Fortunately, however, one of 
the MagForce team’s publications – the Johannsen et al. 2007 report on a clinical study 
of magnetic hyperthermia in 10 prostate cancer patients [61] – does provide suitably 
specific data: viz. thermal probe measurements of the maximum temperature ΔTmax 
attained at the magnetic fluid injection site for both the first and last heating sessions for 
each patient; and CT scan data for each patient and session. The latter is important as it 
allows estimates to be made of both the retention factor ℛ (which ranged from ca. 0.8 to 
1.0 between individuals, and in some cases fell between treatments) and the dispersion 
factor v (which ranged from ca. 1.0 to 2.2 between individuals, and generally increased 
between treatments).  
With this information at hand we can then compare the measured ΔTmax to the 
maximum temperature predicted from Equation (8), viz. the temperature achieved at the 
central point, r = 0:  
 ∆𝑇NOP ≃ 1.5	 48𝜋X𝑣 −13 	 𝐼𝐿𝑃	𝐻2	𝑓	𝑘2 	𝑐	(ℛ𝑉%)23   , (12) 
where we take into account the possibility of non-ideal retention by including ℛ as a 
scaling factor to the injectate volume 𝑉%, and where the pre-factor 1.5 represents the 
factor 1 + kX 2ke  in the case that 𝑘e ≈ 𝑘X. Strictly speaking the latter is only valid 
for materials such as magnetite, Fe3O4, where the thermal conductivity contribution of 
the particles is negligible compared to that of the tissue itself. (Concentration dependent 
data show that even at 100 mgFe/ml the contribution would be ca. 5 mW/Km [85], 
which is less than 1% of the 𝑘X ≈ 0.52 W/Km of the prostate [80].) The last parameter 
needed to compute Equation (12) is the intrinsic loss power of the magnetic particles. 
For this we use an ILP of ca. 0.4 nHm2/kg inferred from the rat model heating curves 
reported in an earlier MagForce paper [86]. (Further details on this, and other aspects of 
the data handling, are given in the Supplementary Information, section S3.) 
The resultant comparison between predicted and clinically observed ΔTmax 
values is shown in Figure 4. The expected over-estimation of ΔTmax due to having 
neglected the thermally moderating effects of blood perfusion and tissue metabolism is 
clearly evident, but it is also apparent that the approximation becomes better as ΔTmax 
increases. This is logical, given that as more and more heat is deposited into the tissue, 
the body’s capacity to physiologically regulate and overcome that thermal load becomes 
less and less effective. Furthermore, it is possible that at high ΔTmax values there could 
be physical (ablative) damage to the vascular bed that would disrupt blood flow, and 
lead to reduced or even zero perfusion. That said, the somewhat surprising aspect of the 
data in Figure 4 is that the conditions under which the perfusion and metabolism effects 
seem to be overwhelmed come at ΔTmax ≈ 12 K, which corresponds to ΔTR ≈ 8 K, which 
is a target value that one might realistically seek to achieve in a therapeutic 
hyperthermia intervention. Another positive aspect of Figure 4 is that it opens the 
prospect of applying a post-hoc, clinical (or preclinical) observation-based correction to 
the analytical model, which in some situations might be useful. (We illustrate this in the 
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Supplementary Information, section S3, for the case of the Johanssen et al. 2007 
prostate cancer patients.) We conclude therefore that the zero-perfusion, zero-
metabolism analytical model is actually a reasonable first-approximation model of 
therapeutic effect, and that so long as it is used advisedly and cautiously, it represents a 
useful tool for practical purposes. 
6. Conclusions 
Magnetic hyperthermia is a highly promising therapeutic modality that has commanded 
substantial international R&D effort and funding for a decade or more. However, the 
vast majority of reported work to date is laboratory based, or at most preclinical. There 
have been very few reports on the development of clinical studies of magnetic 
hyperthermia, and therefore very little in the way of accumulated knowledge as to how 
such translation can be achieved.  
In this work we have attempted to address this lack of experience-based 
information from a more pedagogical perspective. Specifically, we have considered 
how to manage the transition from preclinical to clinical studies from first principles, 
and have focused on some of the unique aspects of the intervention – such as the strong 
dependence of efficacy on the local concentration of the delivered magnetic heating 
agent – that make it so different from more conventional treatments. In particular, we 
have reviewed the ethical and regulatory guidelines for both interstitial and intravenous 
injections of magnetic agents, and established that while the former scales between 
species as a function of body surface area, the latter translates as a species-independent 
local concentration.  
In addition, we have reviewed current benchmarks in the form of commercially 
available iron oxide based magnetic fluids that have clinical applications, and thereby 
derived quantitative rules-of-thumb regarding the clinically acceptable dosage limits for 
both their intravenous and interstitial administration. From this we have shown that by 
applying suitable theoretical models of clinical efficacy (based on biophysical models of 
heat flows in tissue) it is possible to establish design parameters that inform the 
formulation criteria required for any given target intervention. Furthermore, we have 
shown that these same biophysical models can then inform the design of the 
corresponding preclinical models that are needed to establish the positive therapeutic 
benefits of the hyperthermia treatment, as a necessary step towards obtaining 
permission to proceed to first-in-man studies. 
It is our hope that setting out the framework for systematically establishing the 
link between preclinical and clinical study designs in this way may prove to be useful 
for others, and that in the near future we might see many more clinical studies of 
therapeutic magnetic hyperthermia being undertaken, for the benefit of us all. 
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Table 1. Exemplar guidelines for the maximum injection volumes of experimental 
compounds in mice, rats, rabbits and humans (of the given FDA reference body 
weights) on the basis of the administration route, as used by the Duke University 
Medical Center in Durham, NC, USA [47]. 
 







Subcutaneous 2 ml/site 10 ml/site 50 ml/site 2 ml/site 
Intramuscular 0.1 ml/site 0.3 ml/site 0.5 ml/site 5 ml/site 
Intraperitoneal 3 ml 10 ml 100 ml 5 ml 
Intravenous 0.2 ml 0.5  ml 5 ml 250 ml 
Intradermal 0.05 ml/site 0.05 ml/site 0.1 ml/site 0.1 ml/site 
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Figure 1. Equilibrium temperature profile ΔT (r ) within and surrounding a sphere of 
radius R of a medium of thermal conductivity 𝑘e within a medium of thermal 
conductivity 𝑘X, after prolonged exposure to an energy source depositing power P into 
the sphere [74]. The solid lines represent solutions to Equation (8) for values of the ratio 𝑘e/𝑘X ranging from 1.0 to 2.0, plotted in the reduced coordinate system where r¢ = r / R, 
and ΔT¢  (r¢ ) = 3𝑘X ΔT (r ) / PR2. 
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Figure 2. Illustrative bioheat model calculations in the steady-state, zero perfusion, zero 
metabolic heat generation limit, for a 60 kg human, as per Equation (10), showing ΔTR 
isotherms in the Vi-c plane, where ΔTR is the equilibrium temperature at the surface of a 
sphere of radius R containing a uniform distribution of heat-evolving magnetic 
nanoparticles. Assumed parameters are: intrinsic loss power ILP = 3.0 nHm2/kgFe; 
dispersion factor v = Vd/Vi = 2.4; thermal conductivity of the surrounding medium λ2 = 
0.52 W/Km; and activation field amplitude H = 5 kA/m and frequency f = 300 kHz. The 
shaded region demarcates the clinically acceptable dose region, as determined from 
both the material loading capacities of the local tissue, viz. 40 mgFe/mltissue, and of the 
body as a whole, viz. 850 mgFe. The latter value is derived, as per Equation (6), 
assuming a ‘good’ agent formulation scenario of relatively high retention (ℛ = 0.85) 
and systemic tolerance (ℱ = 0.85). The points A and B denote two possible treatment 
scenarios, as discussed in the text. 
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Figure 3. Illustrative bioheat model calculations in the steady-state, zero perfusion, zero 
metabolic heat generation limit, for a 20 g mouse, as per Equation (10), under the same 
material conditions as in Figure 2, viz. ILP = 3.0 nHm2/kgFe, v = Vd/Vi = 2.4, and λ2 = 
0.52 W/Km. The solid lines are ΔTR = 6 K isotherms, indicating the thresholds for 
therapeutic hyperthermia. The shaded region demarcates the murine ‘acceptable dose 
region’, as determined from both the material loading capacities of the local tissue, viz. 
40 mgFe/mltissue, and of the mouse as a whole, viz. 3.5 mgFe. The latter value is derived, 
as per Equation (6), assuming a ‘good’ agent formulation scenario of relatively high 
retention (ℛ = 0.85) and systemic tolerance (ℱ = 0.85). The red line, corresponding to 
H = 5 kA/m and f = 300 kHz (the same conditions as in Figure 2), lies outside the 
acceptable dose region, and as such is inaccessible. The black line, corresponding to H 
= 10 kA/m and f = 1 MHz, lies within the acceptable dose region, as therefore is 
accessible. The points A, A¢, B and B¢ are discussed in the text.  
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Figure 4. Comparison between maximum temperature rises ΔTmax due to magnetic 
heating as calculated using the first-order approximation method of Equations (8) and 
(10), and the reported ΔTmax for a clinical study of prostate cancer patients undertaken 
by the MagForce team [61]. The limitations of the zero-perfusion, zero-metabolism 
model are evident at the lower ΔTmax values, but the model is more valid as ΔTmax 
increases. The arrow denotes the ΔTmax value for which the temperature of the entire 
magnetic-nanoparticle-infused tissue volume reaches the therapeutically significant 
value of ΔT = 6 K or above. The dashed line is a guide to the eye only. 
 
 
